Cargando…
Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project)
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) which has rapidly spread worldwide. Several human randomized clinical trials assessing potential vaccines are currently underway. There is an urgent need for a living systematic review...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678579/ https://www.ncbi.nlm.nih.gov/pubmed/33218366 http://dx.doi.org/10.1186/s13643-020-01516-1 |
_version_ | 1783612186283737088 |
---|---|
author | Korang, Steven Kwasi Juul, Sophie Nielsen, Emil Eik Feinberg, Joshua Siddiqui, Faiza Ong, Giok Klingenberg, Sarah Veroniki, Areti Angeliki Bu, Fanlong Thabane, Lehana Thomsen, Allan Randrup Jakobsen, Janus C. Gluud, Christian |
author_facet | Korang, Steven Kwasi Juul, Sophie Nielsen, Emil Eik Feinberg, Joshua Siddiqui, Faiza Ong, Giok Klingenberg, Sarah Veroniki, Areti Angeliki Bu, Fanlong Thabane, Lehana Thomsen, Allan Randrup Jakobsen, Janus C. Gluud, Christian |
author_sort | Korang, Steven Kwasi |
collection | PubMed |
description | BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) which has rapidly spread worldwide. Several human randomized clinical trials assessing potential vaccines are currently underway. There is an urgent need for a living systematic review that continuously assesses the beneficial and harmful effects of all available vaccines for COVID-19. METHODS/DESIGN: We will conduct a living systematic review based on searches of major medical databases (e.g., MEDLINE, EMBASE, CENTRAL) and clinical trial registries from their inception onwards to identify relevant randomized clinical trials. We will update the literature search once a week to continuously assess if new evidence is available. Two review authors will independently extract data and conduct risk of bias assessments. We will include randomized clinical trials comparing any vaccine aiming to prevent COVID-19 (including but not limited to messenger RNA; DNA; non-replicating viral vector; replicating viral vector; inactivated virus; protein subunit; dendritic cell; other vaccines) with any comparator (placebo; “active placebo;” no intervention; standard care; an “active” intervention; another vaccine for COVID-19) for participants in all age groups. Primary outcomes will be all-cause mortality; a diagnosis of COVID-19; and serious adverse events. Secondary outcomes will be quality of life and non-serious adverse events. The living systematic review will include aggregate data meta-analyses, trial sequential analyses, network meta-analyses, and individual patient data meta-analyses. Within-study bias will be assessed using Cochrane risk of bias tool. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) and Confidence in Network Meta-Analysis (CINeMA) approaches will be used to assess certainty of evidence. Observational studies describing harms identified during the search for trials will also be included and described and analyzed separately. DISCUSSION: COVID-19 has become a pandemic with substantial mortality. A living systematic review assessing the beneficial and harmful effects of different vaccines is urgently needed. This living systematic review will regularly inform best practice in vaccine prevention and clinical research of this highly prevalent disease. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020196492 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13643-020-01516-1. |
format | Online Article Text |
id | pubmed-7678579 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-76785792020-11-23 Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project) Korang, Steven Kwasi Juul, Sophie Nielsen, Emil Eik Feinberg, Joshua Siddiqui, Faiza Ong, Giok Klingenberg, Sarah Veroniki, Areti Angeliki Bu, Fanlong Thabane, Lehana Thomsen, Allan Randrup Jakobsen, Janus C. Gluud, Christian Syst Rev Protocol BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) which has rapidly spread worldwide. Several human randomized clinical trials assessing potential vaccines are currently underway. There is an urgent need for a living systematic review that continuously assesses the beneficial and harmful effects of all available vaccines for COVID-19. METHODS/DESIGN: We will conduct a living systematic review based on searches of major medical databases (e.g., MEDLINE, EMBASE, CENTRAL) and clinical trial registries from their inception onwards to identify relevant randomized clinical trials. We will update the literature search once a week to continuously assess if new evidence is available. Two review authors will independently extract data and conduct risk of bias assessments. We will include randomized clinical trials comparing any vaccine aiming to prevent COVID-19 (including but not limited to messenger RNA; DNA; non-replicating viral vector; replicating viral vector; inactivated virus; protein subunit; dendritic cell; other vaccines) with any comparator (placebo; “active placebo;” no intervention; standard care; an “active” intervention; another vaccine for COVID-19) for participants in all age groups. Primary outcomes will be all-cause mortality; a diagnosis of COVID-19; and serious adverse events. Secondary outcomes will be quality of life and non-serious adverse events. The living systematic review will include aggregate data meta-analyses, trial sequential analyses, network meta-analyses, and individual patient data meta-analyses. Within-study bias will be assessed using Cochrane risk of bias tool. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) and Confidence in Network Meta-Analysis (CINeMA) approaches will be used to assess certainty of evidence. Observational studies describing harms identified during the search for trials will also be included and described and analyzed separately. DISCUSSION: COVID-19 has become a pandemic with substantial mortality. A living systematic review assessing the beneficial and harmful effects of different vaccines is urgently needed. This living systematic review will regularly inform best practice in vaccine prevention and clinical research of this highly prevalent disease. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020196492 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13643-020-01516-1. BioMed Central 2020-11-20 /pmc/articles/PMC7678579/ /pubmed/33218366 http://dx.doi.org/10.1186/s13643-020-01516-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Protocol Korang, Steven Kwasi Juul, Sophie Nielsen, Emil Eik Feinberg, Joshua Siddiqui, Faiza Ong, Giok Klingenberg, Sarah Veroniki, Areti Angeliki Bu, Fanlong Thabane, Lehana Thomsen, Allan Randrup Jakobsen, Janus C. Gluud, Christian Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project) |
title | Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project) |
title_full | Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project) |
title_fullStr | Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project) |
title_full_unstemmed | Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project) |
title_short | Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project) |
title_sort | vaccines to prevent covid-19: a protocol for a living systematic review with network meta-analysis including individual patient data (the living vaccine project) |
topic | Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678579/ https://www.ncbi.nlm.nih.gov/pubmed/33218366 http://dx.doi.org/10.1186/s13643-020-01516-1 |
work_keys_str_mv | AT korangstevenkwasi vaccinestopreventcovid19aprotocolforalivingsystematicreviewwithnetworkmetaanalysisincludingindividualpatientdatathelivingvaccineproject AT juulsophie vaccinestopreventcovid19aprotocolforalivingsystematicreviewwithnetworkmetaanalysisincludingindividualpatientdatathelivingvaccineproject AT nielsenemileik vaccinestopreventcovid19aprotocolforalivingsystematicreviewwithnetworkmetaanalysisincludingindividualpatientdatathelivingvaccineproject AT feinbergjoshua vaccinestopreventcovid19aprotocolforalivingsystematicreviewwithnetworkmetaanalysisincludingindividualpatientdatathelivingvaccineproject AT siddiquifaiza vaccinestopreventcovid19aprotocolforalivingsystematicreviewwithnetworkmetaanalysisincludingindividualpatientdatathelivingvaccineproject AT onggiok vaccinestopreventcovid19aprotocolforalivingsystematicreviewwithnetworkmetaanalysisincludingindividualpatientdatathelivingvaccineproject AT klingenbergsarah vaccinestopreventcovid19aprotocolforalivingsystematicreviewwithnetworkmetaanalysisincludingindividualpatientdatathelivingvaccineproject AT veronikiaretiangeliki vaccinestopreventcovid19aprotocolforalivingsystematicreviewwithnetworkmetaanalysisincludingindividualpatientdatathelivingvaccineproject AT bufanlong vaccinestopreventcovid19aprotocolforalivingsystematicreviewwithnetworkmetaanalysisincludingindividualpatientdatathelivingvaccineproject AT thabanelehana vaccinestopreventcovid19aprotocolforalivingsystematicreviewwithnetworkmetaanalysisincludingindividualpatientdatathelivingvaccineproject AT thomsenallanrandrup vaccinestopreventcovid19aprotocolforalivingsystematicreviewwithnetworkmetaanalysisincludingindividualpatientdatathelivingvaccineproject AT jakobsenjanusc vaccinestopreventcovid19aprotocolforalivingsystematicreviewwithnetworkmetaanalysisincludingindividualpatientdatathelivingvaccineproject AT gluudchristian vaccinestopreventcovid19aprotocolforalivingsystematicreviewwithnetworkmetaanalysisincludingindividualpatientdatathelivingvaccineproject |